EU industry: new PV fee plan better, but still much room for improvement
This article was originally published in Scrip
Groups representing the innovator and generic pharmaceutical industries in Europe have welcomed the changes made by the European Commission to its original plans for a pharmacovigilance fee system, but say that there are still major problems with the proposal.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.